CN103842372A - 环孢菌素衍生物 - Google Patents

环孢菌素衍生物 Download PDF

Info

Publication number
CN103842372A
CN103842372A CN201280042682.1A CN201280042682A CN103842372A CN 103842372 A CN103842372 A CN 103842372A CN 201280042682 A CN201280042682 A CN 201280042682A CN 103842372 A CN103842372 A CN 103842372A
Authority
CN
China
Prior art keywords
compound
formula
group
alkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280042682.1A
Other languages
English (en)
Chinese (zh)
Inventor
G·菲舍尔
M·马勒赛维克
F·厄德曼
J·库灵
M·布克里恩斯基
S·库恩斯坦特
G·鲁特
P·努斯巴姆尔
K·蒂恩克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lead Discovery Center GmbH
Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Original Assignee
Lead Discovery Center GmbH
Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Discovery Center GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV filed Critical Lead Discovery Center GmbH
Publication of CN103842372A publication Critical patent/CN103842372A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
CN201280042682.1A 2011-08-30 2012-08-29 环孢菌素衍生物 Pending CN103842372A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011111991A DE102011111991A1 (de) 2011-08-30 2011-08-30 Neue Cyclosporin-Derivate
DE102011111991.8 2011-08-30
PCT/EP2012/066726 WO2013030208A1 (de) 2011-08-30 2012-08-29 Cyclosporin-derivate

Publications (1)

Publication Number Publication Date
CN103842372A true CN103842372A (zh) 2014-06-04

Family

ID=46754993

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280042682.1A Pending CN103842372A (zh) 2011-08-30 2012-08-29 环孢菌素衍生物

Country Status (9)

Country Link
US (1) US9453051B2 (cg-RX-API-DMAC7.html)
EP (1) EP2751127B1 (cg-RX-API-DMAC7.html)
JP (1) JP6240072B2 (cg-RX-API-DMAC7.html)
CN (1) CN103842372A (cg-RX-API-DMAC7.html)
AU (1) AU2012300934B2 (cg-RX-API-DMAC7.html)
CA (1) CA2845663C (cg-RX-API-DMAC7.html)
DE (1) DE102011111991A1 (cg-RX-API-DMAC7.html)
ES (1) ES2601029T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013030208A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0737730Y2 (ja) 1989-10-04 1995-08-30 横河電機株式会社 溶射装置
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
CN104513296B (zh) * 2013-09-27 2018-03-02 王喆明 一种环肽化合物及其用途
WO2016112295A1 (en) 2015-01-09 2016-07-14 Warp Drive Bio, Inc. Compounds that participate in cooperative binding and uses thereof
CA3000822A1 (en) * 2015-10-01 2017-04-06 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
CA3020594A1 (en) 2016-04-12 2017-10-19 Warp Drive Bio, Inc. Compositions and methods for the production of compounds
US12594275B2 (en) 2019-02-07 2026-04-07 The Regents Of The University Of California Immunophilin binding agents and uses thereof
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN121471132A (zh) 2019-11-04 2026-02-06 锐新医药公司 Ras抑制剂
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021173474A1 (en) * 2020-02-26 2021-09-02 Bacainn Biotherapeutics, Ltd. Cyclosporine compositions and methods of use
CA3172535A1 (en) * 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
WO2022192716A1 (en) * 2021-03-11 2022-09-15 Massachusetts Institute Of Technology Small molecule suppressors of apoe gene expression and cerebral vascular amyloid pathology
CN112919984B (zh) * 2021-04-16 2022-03-08 安徽硒无忧现代农业科技有限公司 一种生态化富硒有机营养液及其制备方法
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2205317A (en) * 1987-06-03 1988-12-07 Merck & Co Inc New cyclosporin analogs with modified }c-9-amino acids}
US20060069016A1 (en) * 2004-09-29 2006-03-30 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US20100009390A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1506200A (en) * 1975-04-30 1978-04-05 Farmaceutici Italia Glycosides
US4672044A (en) 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
GB8426672D0 (en) * 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
AT401823B (de) 1993-09-30 1996-12-27 Avl Verbrennungskraft Messtech Optischer indikator zur bestimmung der aktivität eines ions in einer probe
AUPO395396A0 (en) 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
PT848009E (pt) * 1996-12-16 2000-11-30 Pharmachemie Bv Processo para a preparacao de epirubicina ou seus sais de adicao de acido a partir de daunorubicina
CA2285454A1 (en) 1997-04-07 1998-10-15 Axys Pharmaceuticals Corporation Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DE69832984T2 (de) 1997-10-08 2006-09-21 Isotechnika, Inc., Edmonton DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
WO2000020400A1 (en) 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
DE19859910C2 (de) 1998-12-23 2001-03-22 Ratiopharm Gmbh Orales Arzneimittel
IL135884A (en) 2000-04-30 2005-08-31 Yissum Res Dev Co Method for measuring non-transferrin bound iron
US6596499B2 (en) 2000-11-30 2003-07-22 The Netherlands Cancer Institute Membrane molecule indicator compositions and methods
US6784156B2 (en) * 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
WO2003087089A1 (en) 2002-04-16 2003-10-23 Teijin Limited Piperidine derivatives having ccr3 antagonism
AU2003285958A1 (en) 2002-10-25 2004-05-25 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
WO2005004805A2 (en) * 2003-07-02 2005-01-20 Solux Corporation Thermally stable crystalline epirubicin hydrochloride and method of making the same
US20090099346A1 (en) * 2003-07-02 2009-04-16 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride
DE10339597A1 (de) 2003-08-26 2005-03-31 Bayer Technology Services Gmbh Vorrichtung und Verfahren zum Nachweis biochemischer Aktivität enthaltend Gap Junctions
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
DE102006038403A1 (de) 2006-08-17 2008-02-21 Heinrich-Heine-Universität Düsseldorf Verwendung bestimmter chemischer Verbindungen zur Inhibierung der Peptidyl-Prolyl-cis/trans-Isomeraseaktivität von Cyclophilinen
SG144809A1 (en) 2007-01-11 2008-08-28 Millipore U K Ltd Benzimidazole compounds and their use as chromatographic ligands
PL1990405T3 (pl) * 2007-05-08 2018-01-31 Provivo Oy Genetycznie zmodyfikowane szczepy wytwarzające metabolity będące antracyklinami użyteczne jako leki przeciwnowotworowe
MX2011001152A (es) 2008-07-30 2011-06-09 Isotechnika Pharma Inc Moleculas de analogo de ciclosporina no-inmunesupresoras.
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US8481483B2 (en) * 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
DE102009037551A1 (de) 2009-08-17 2011-02-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cyclosporinderivate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2205317A (en) * 1987-06-03 1988-12-07 Merck & Co Inc New cyclosporin analogs with modified }c-9-amino acids}
US20060069016A1 (en) * 2004-09-29 2006-03-30 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US20100009390A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr

Also Published As

Publication number Publication date
ES2601029T3 (es) 2017-02-14
WO2013030208A1 (de) 2013-03-07
EP2751127B1 (de) 2016-07-27
CA2845663A1 (en) 2013-03-07
AU2012300934B2 (en) 2016-06-09
AU2012300934A1 (en) 2014-03-13
EP2751127A1 (de) 2014-07-09
US9453051B2 (en) 2016-09-27
CA2845663C (en) 2020-09-08
DE102011111991A1 (de) 2013-02-28
JP6240072B2 (ja) 2017-11-29
JP2014531417A (ja) 2014-11-27
US20140316104A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
CA2845663C (en) Cyclosporin derivatives
TWI882061B (zh) 介白素-23受體之肽抑制劑及其治療發炎性疾病之用途
KR20240034223A (ko) 인터류킨-23 수용체의 바이사이클릭 펩티드 억제제
US12421276B2 (en) Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues
KR100579748B1 (ko) 돌라스타틴 15 유도체
JP2007501866A (ja) 胃腸疾患の治療のための方法および組成物
CN110240629A (zh) 蛋白降解靶向bcr-abl化合物及其抗肿瘤应用
CN102159589A (zh) 神经肽-2受体(y-2r)激动剂及其用途
CN116209671A (zh) 补体因子c3的抑制剂及其医学用途
WO2012142142A2 (en) Adiponectin receptor agonists and methods of use
US9561290B2 (en) Functionalized thieno-indole derivatives for the treatment of cancer
KR20260038313A (ko) 글리피칸-3을 표적화하는 펩티드 조성물 및 그의 용도
CN114890990B (zh) 一种化合物及在制备nampt蛋白自噬降解剂中的应用
US11866518B2 (en) Bicyclic peptide ligands specific for TSLP
HK1195916A (en) Cyclosporin derivatives
WO2019181901A1 (ja) 細胞移植を効率化する化合物
TW202426031A (zh) EphA2結合待定肽及包含其之組成物
CN101578287B (zh) 地索拉唑及其衍生物与细胞结合分子的轭合物,新的地索拉唑衍生物,其制备方法及其应用
CN120435304A (zh) Ccr2抑制剂及使用方法
US10385096B2 (en) Pro-Amb reverse turn restricted bioactive peptide analogues
CN118852453A (zh) 肠促胰素类似物及其制备方法和应用
HK40056369B (en) Pyrimidine compound or salt thereof
KR20250135269A (ko) 인터루킨-23 수용체의 펩티드 억제제
BR122024027151A2 (pt) Peptídeos monocíclicos e seus usos
BR122024027142A2 (pt) Inibidor peptídico do receptor de interleucina-23, composição farmacêutica, e uso dos mesmos

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1195916

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140604

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1195916

Country of ref document: HK